Chromodulin–Insulin receptor complex (None established)

Chromodulin is a low-molecular-weight, chromium-binding oligopeptide (~1500 Da) composed of glutamate, glycine, cysteine, and aspartate residues, which binds four Cr^3+^ ions[4][6][8]. It interacts with the insulin receptor by enhancing its tyrosine kinase activity, promoting insulin signaling and glucose uptake—a process relevant to the regulation of carbohydrate and lipid metabolism and management of insulin resistance and type 2 diabetes[3][7][8]. The insulin receptor itself is a transmembrane receptor tyrosine kinase crucial for cellular responses to insulin including glucose uptake, metabolism, and cell growth[1][5]. The Chromodulin–Insulin receptor complex is not a unique molecular entity but a functional interaction involved in metabolic regulation. Notably, the exact amino acid sequence and structure of chromodulin remain partially unresolved, and its mechanism in vivo is still under investigation[4][6][8]. In summary, the request describes a non-canonical complex (chromodulin/insulin receptor complex); the two components are best analyzed separately. Chromodulin modulates insulin receptor function, but is not a formal therapeutic drug target. Insulin receptor is a validated drug target for diabetes and related diseases. Chromodulin’s molecular composition and interaction with the insulin receptor are still being elucidated.

Other names

ChromodulinLow-molecular-weight chromium-binding substanceLMWCrInsulin receptorIR

Insulin receptor: Insulin binding leads to receptor autophosphorylation, downstream signaling. Chromodulin: Binds chromium ions, interacts with insulin receptor to amplify tyrosine kinase activity, enhancing insulin signal.